Finance

Lists
3349:TYO
Cosmos Pharmaceutical Corp
Â¥6,459.00
+0.02%
(+1.00) 1D
Oct 19, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 3349...
Open
Â¥6,558
High
Â¥6,582
Low
Â¥6,427
Mkt. cap
516.73B
Avg. vol.
483.37K
Volume
522.30K
Dividend
1.27%
Quarterly dividend
Â¥21
Ex-dividend date
Nov 27, 2026
P/E ratio
15.93
52-wk high
Â¥8,121
52-wk low
Â¥5,615
EPS
Â¥405
Shares outstanding
19.80M
No. of employees
6K
Open
Â¥6,558
High
Â¥6,582
Low
Â¥6,427
Mkt. cap
516.73B
Avg. vol.
483.37K
Volume
522.30K
Dividend
1.27%
Quarterly dividend
Â¥21
Ex-dividend date
Nov 27, 2026
P/E ratio
15.93
52-wk high
Â¥8,121
52-wk low
Â¥5,615
EPS
Â¥405
Shares outstanding
19.80M
No. of employees
6K
News stories
From web sources and news partners
About Cosmos Pharmaceutical Corp
CEO-
Employees5.98K
FoundedDec 1983
Headquarters-
SectorDrug
Last report
Oct 13, 2026
Fiscal period
Q1 2027
- / -
Revenue / Est. (JPY)
286.65B / 291.21B
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Nov 2025
Feb 2026
May 2026
Aug 2026
Revenue
264.78B
273.20B
289.20B
286.65B
Cost of goods sold
209.07B
216.15B
229.46B
224.52B
Cost of revenue
209.07B
216.15B
229.46B
224.52B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
46.57B
45.83B
26.43B
50.24B
Operating expense
46.57B
45.83B
49.08B
50.24B
Total operating expenses
255.64B
261.97B
278.54B
274.76B
Operating income
9.14B
11.23B
10.66B
11.89B
Other non operating income
801.00M
667.00M
695.00M
958.00M
EBT including unusual items
9.58B
11.96B
10.60B
12.36B
EBT excluding unusual items
9.85B
11.81B
11.12B
12.61B
Income tax expense
3.10B
3.86B
1.30B
4.11B
Effective tax rate
32.35%
32.26%
12.26%
33.23%
Other operating expenses
-
-
-
-
Net income
6.48B
8.10B
9.30B
8.25B
Net profit margin
2.45%
2.96%
3.21%
2.88%
Earnings per share
-
-
-
-
Interest and investment income
19.00M
16.00M
12.00M
46.00M
Interest expense
-107.00M
-107.00M
-257.00M
-281.00M
Net interest expenses
-88.00M
-91.00M
-245.00M
-235.00M
Depreciation and amortization charges
-
-
22.64B
-
EBITDA
15.00B
16.79B
16.81B
18.03B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google apps